CLINICAL TRIALS PROFILE FOR FLOMAX

All Clinical Trials for FLOMAX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00209131 ↗	Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy	Terminated	Emory University	N/A	2005-04-01	The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00244309 ↗	Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer	Completed	GlaxoSmithKline	Phase 3	2005-11-01	The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or another drug named dutasteride (Avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the rate of intermittent self-catheterization after prostate brachytherapy.
NCT00244309 ↗	Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer	Completed	Case Comprehensive Cancer Center	Phase 3	2005-11-01	The purpose of this study is to determine whether a drug named tamsulosin (Flomax), or another drug named dutasteride (Avodart), or a combination of these two drugs is effective in improving urinary symptoms and decreasing the rate of intermittent self-catheterization after prostate brachytherapy.

Clinical Trial Conditions for FLOMAX

Condition Name

Condition Name for FLOMAX
Intervention	Trials
Prostatic Hyperplasia	6
Benign Prostatic Hyperplasia	6
Urinary Retention	4
Lower Urinary Tract Symptoms	3

Condition MeSH

Condition MeSH for FLOMAX
Intervention	Trials
Prostatic Hyperplasia	13
Hyperplasia	13
Urinary Retention	10
Lower Urinary Tract Symptoms	6

Clinical Trial Locations for FLOMAX

Trials by Country

Trials by Country for FLOMAX
Location	Trials
United States	53
Korea, Republic of	7
Canada	7
Germany	3
Australia	3

Trials by US State

Trials by US State for FLOMAX
Location	Trials
California	5
Georgia	4
New Jersey	3
Alabama	3
New York	3

Clinical Trial Progress for FLOMAX

Clinical Trial Phase

Clinical Trial Phase for FLOMAX
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	16
Phase 3	6

Clinical Trial Status

Clinical Trial Status for FLOMAX
Clinical Trial Phase	Trials
Completed	28
Terminated	5
Unknown status	5

Clinical Trial Sponsors for FLOMAX

Sponsor Name

Sponsor Name for FLOMAX
Sponsor	Trials
GlaxoSmithKline	6
Boehringer Ingelheim	6
Hackensack Meridian Health	2

Sponsor Type

Sponsor Type for FLOMAX
Sponsor	Trials
Other	36
Industry	21
U.S. Fed	2

Last updated: July 28, 2026

Flomax (tamsulosin) clinical trials update, market analysis, and revenue projection

Executive summary

Flomax is the branded alpha-1A/1D adrenergic antagonist tamsulosin (immediate-release and extended-release formulations). Tamsulosin products remain commercial in benign prostatic hyperplasia (BPH) and continue to face generic pressure, with patent-driven brand longevity largely resolved in major markets. Clinical “update” activity has shifted toward label expansions, combination regimens, new dosing/administration approaches, and post-marketing safety evidence rather than foundational phase-3 development. Market growth is muted, driven mostly by population aging and incremental share changes between branded and authorized generics, plus dispensing and payer dynamics.

Bottom line for planning: near-term value is more sensitive to formulation switching, formulary access (including wholesaler/wholesale acquisition cost dynamics in the US), and competitor share than to new mechanism IP. The commercial curve is likely to remain flat-to-low-growth versus competitors’ price erosion patterns unless a meaningful differentiation in delivery system, combination therapy, or guideline position emerges.

---

What clinical trials have been conducted for Flomax (tamsulosin), and what is the latest update?

Featured snippet answer: For Flomax, the most influential evidence base comes from older randomized controlled trials establishing efficacy in BPH symptom relief and urinary flow. Current clinical activity is typically post-approval: head-to-head comparisons of formulations, combination therapy studies (alpha-blocker plus 5-alpha reductase inhibitor or antimuscarinics), and safety follow-up.

What outcomes do current tamsulosin trials focus on?

• Symptom scores (commonly AUA-SI/International Prostate Symptom Score)
• Urinary flow measures (Qmax)
• Acute urinary retention and progression endpoints (less commonly in late-stage studies, more common in longer-term observational and pragmatic trials)
• Tolerability and orthostatic hypotension rates
• Subgroup performance by age, baseline severity, and comorbidities

Which trial types are most common now?

• Formulation and pharmacokinetic bridging studies (IR vs ER, or generics versus reference)
• Switching studies assessing tolerability and adherence
• Combination regimen trials (BPH with overactive bladder symptoms, BPH with urinary retention risk)
• Real-world evidence registries and claims-based studies

How “clinical trials update” should be interpreted for Flomax

Because Flomax is a legacy small-molecule, the most relevant updates for decision-making are:

1. New comparative effectiveness studies that affect payer/provider preference
2. Evidence that changes guideline recommendations or practical use patterns
3. Safety findings that affect risk management and labeling conduct

(Without a specific trial registry feed or named protocol set, a defensible “latest trial list” cannot be produced here.)

---

What is the market size and current commercial performance for Flomax (tamsulosin) in BPH?

Featured snippet answer: Tamsulosin is a mature BPH drug class member with broad generic penetration. Branded revenue is structurally constrained by generic substitutability, with brand performance dependent on payer positioning, channel mix, and the durability of authorized and branded extended-release shares.

Key market drivers

• Aging demographics: higher incidence and prevalence of BPH symptoms with age
• Guideline adherence: sustained alpha-blocker use for LUTS/BPH symptom management
• Combination therapy demand: men with persistent symptoms often receive add-ons, changing treatment pathway shares
• Supply and pricing: generic competition compresses net prices; authorized generics can reduce branded differentiation

Key market constraints

• Generic substitution: reduces branded pricing power
• Payer restrictions: tier placement and step edits can shift prescribing to lower-cost alternatives
• Class competition: other alpha-1 blockers (e.g., silodosin, alfuzosin, doxazosin) compete for formulary share

---

How does Flomax compare with other tamsulosin products and BPH alpha-blockers?

Featured snippet answer: Flomax competes primarily against generic tamsulosin products and against other alpha-blockers. Differentiation most often comes down to formulation attributes (IR vs ER), dosing convenience, and tolerability profiles that can shift prescriber preference.

Common competitive axes

• ER vs IR adherence and symptom control consistency
• Ejaculatory dysfunction incidence (class-relevant tolerability endpoint)
• Orthostatic hypotension rates and labeling warnings impact
• Drug interactions and patient comorbidity fit (antihypertensives, PDE-5 inhibitors, CYP interactions)

Where do formulary decisions usually land?

• Lower net price generics dominate most formularies.
• If brand positioning exists, it typically rests on pharmacy channel relationships, rebates, and ER-specific coverage.

---

When does Flomax lose exclusivity, and what does that imply for brand durability?

Featured snippet answer: Core Flomax exclusivity from the original tamsulosin invention has largely been exhausted; ongoing commercialization depends on remaining formulation- and method-of-use IP and, in some markets, on controlled product line protections or regulatory exclusivity rather than long-term composition patents.

How exclusivity loss typically plays out for mature small molecules

• Composition of matter expires first
• Then remaining secondary protections (formulation, specific dosing regimens, manufacturing method) can delay full generic displacement
• Ultimately authorized generics and multiple ANDA entries drive price compression

Practical implication

Even without identifying specific patent dates here, the business reality is that branded Flomax value tends to track net price and contract structure rather than patent-monopoly time.

---

What is the Orange Book status of Flomax (tamsulosin), and how many patents are listed?

Featured snippet answer: Orange Book listings for tamsulosin-containing products can include patents for formulation and use, but the number of enforceable, unexpired patents is typically limited by the age of the drug.

What to look for in Orange Book entries

• Patent numbers tied to NDA(s) and drug product combinations
• “Drug substance” vs “drug product” vs “methods of use” categories
• Expiration dates and remaining patent term at the time of evaluation
• Whether patents are marked with “Exclusivity” periods or are associated with specific strengths

(An Orange Book table with patent numbers and expiry dates cannot be produced in this response without the underlying Orange Book dataset.)

---

What patent estate protects Flomax formulations and dosing, and how strong is it?

Featured snippet answer: The Flomax patent estate is dominated by legacy patents that are mostly expired, with remaining value concentrated in later-cycle formulation or method-of-use patents if still active in a given jurisdiction.

Common protection categories for tamsulosin line extensions

• Controlled-release or modified-release formulation patents
• Manufacturing and particle/solid-state property patents
• Method-of-use patents tied to BPH symptom subsets or combination therapy regimens

How to assess “strength” in litigation terms

• How many remaining unexpired patents exist
• Whether those patents are “thin” (narrow claims that are easy to design around)
• Whether key patents are marked to Orange Book and thus are typically targets in Paragraph IV litigation

(Without a specific patent list, strength scoring cannot be completed here.)

---

Are there any Paragraph IV challenges for Flomax (tamsulosin) and what settlements occurred?

Featured snippet answer: For mature tamsulosin products, Paragraph IV filings are common historically, with many resolved by settlements or by commercial entry after patent expiry. Current-period Paragraph IV activity is less often the main driver of market dynamics unless a still-active patent blocks an ER or specific strength.

What matters for business planning

• Settlement dates and the “carve-out” of launch design changes
• Whether the settlement enabled an earlier-than-expiry entry for specific strengths
• Whether exclusivity terms triggered authorized generic launch timing

A litigation timeline with named cases cannot be provided without a case dataset.

---

What biosimilar risk applies to Flomax (tamsulosin)?

Featured snippet answer: No biosimilar pathway applies. Flomax is a small molecule, not a biologic.

Alternative competitive risk

• ANDA generics and authorized generics
• Controlled-release and generic formulation switching
• Therapeutic class substitution to other alpha-blockers

---

What formulation patents are relevant to Flomax (ER vs IR), and what generic entry risks exist?

Featured snippet answer: If ER-specific patents or formulation-specific method-of-manufacture protections remain active, they can slow generic entry or force design-around formulations. With a legacy product, these risks are usually limited to narrow, formulation-dependent claims rather than broad composition.

Generic entry risk channels

• Design-around of release kinetics or excipient systems
• Avoidance of manufacturing method claims
• Strength-by-strength approval timing differences in ANDAs
• Labeling carve-outs affecting substitution and switching

(Exact generic entry risk and timelines require an Orange Book patent table and ANDA approval history.)

---

What FDA regulatory status does Flomax have, including approvals and labeling?

Featured snippet answer: Flomax has FDA approval for BPH symptom improvement. Regulatory status is stable for a mature drug; business-relevant changes are usually labeling updates, safety communications, and formulation manufacturing changes.

What to track for FDA-linked business changes

• Label safety updates that alter prescriber behavior
• Any REMS-like controls (rare for this class)
• Labeling changes affecting perioperative risk (cataract surgery related issues are class-relevant for alpha-1 antagonists)

A structured FDA timeline cannot be produced here without citing the specific FDA labeling revision history.

---

Market projection for Flomax (tamsulosin): 3-year revenue outlook

Featured snippet answer: The most likely scenario is flat-to-low-growth branded revenue with ongoing erosion from price compression and share loss to generics and authorized generics. Total category volume likely rises modestly with aging demographics, but brand net revenue growth is unlikely to track category growth.

Scenario framework (directional)

• Base case: low single-digit growth in category volume, mid-to-high single-digit decline in branded net price offset by partial share stabilization
• Downside: faster switching to lower-cost generics, formulary exclusions, and greater competitive substitution among alpha-blockers
• Upside: improved payer access due to contract position, or differentiated ER performance leading to incremental share gains

What determines the slope

• Net price erosion rate (rebates, WAC-to-NADAC spread, channel mix)
• Strength and formulation mix (ER vs IR)
• Competitive entries that shift relative pricing and coverage
• Guideline or safety-driven prescribing patterns

(Quantitative revenue projections require current brand revenue baselines, market share data, and net price inputs that are not provided in this request.)

---

Key assumptions that drive Flomax forecasts

• BPH drug utilization remains stable with aging
• Generic substitution continues as dominant pricing behavior
• No major mechanism shift occurs that displaces alpha-1 blockade as first-line symptom therapy
• New clinical findings primarily refine tolerability/combination use, not replace the class

---

Key Takeaways

• Flomax (tamsulosin) is a mature BPH therapy where clinical relevance is shifting from phase-3 novelty to comparative effectiveness, combination therapy evidence, and safety monitoring.
• Market growth is mainly demographic and treatment-pathway driven, while branded revenue is constrained by generic and authorized generic dynamics.
• Exclusivity and Orange Book-driven brand durability are largely resolved for the core molecule; remaining leverage, if any, is typically narrow formulation or method-of-use protection.
• Forecasts should be built around net price erosion, formulary access, and strength/formulation mix rather than new clinical trial “breakthroughs.”

---

FAQs

1. How do ER vs IR tamsulosin formulations affect adherence and payer coverage?
2. What combination therapies most often add to tamsulosin in BPH patients with persistent LUTS?
3. What safety signals or labeling updates most influence alpha-1 blocker prescribing behavior?
4. How should companies model ANDA entry risk for legacy tamsulosin strengths and formulations?
5. Does tamsulosin competition from silodosin and other alpha-blockers change forecast assumptions for Flomax?

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA Orange Book database).
2. FDA Prescribing Information for Flomax (tamsulosin hydrochloride). U.S. Food and Drug Administration. (Accessed via DailyMed/FDA label repository).